Minerva Neurosciences
NERV
25 hedge funds and large institutions have $18.6M invested in Minerva Neurosciences in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
148% more capital invested
Capital invested by funds: $7.51M → $18.6M (+$11.1M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
9% more funds holding
Funds holding: 23 → 25 (+2)
4.51% less ownership
Funds ownership: 42.5% → 38% (-4.5%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
57% less call options, than puts
Call options by funds: $217K | Put options by funds: $510K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$1.48M |
| 2 |
Renaissance Technologies
New York
|
+$392K |
| 3 |
BlackRock
New York
|
+$164K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$148K |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
+$65.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.95M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.13M |
| 3 |
Millennium Management
New York
|
-$303K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$129K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$126K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| – | -$28K | -8,430 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$13K | -3,995 | Closed |
|
28
Citigroup
New York
| – | -$7K | -2,125 | Closed |
|
NERV Hedge Fund Activity: Q3 2022 in Review
25 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q3 2022, worth a combined $18.6M — up 148% from $7.51M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NERV positions and 5 closed out — a net gain of 2 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Artal Group, opening a new position worth an estimated $1.48M. The largest seller was Vanguard Group, cutting an estimated $1.95M.
- 25 institutional investors held Minerva Neurosciences (NERV) as of Q3 2022, up from 23 in Q2 2022.
- Funds reported $18.6M of Minerva Neurosciences stock for Q3 2022, up 148% quarter-over-quarter.
- 7 funds opened new Minerva Neurosciences positions in Q3 2022 and 5 closed out, a net change of +2 holders.
- The largest Minerva Neurosciences buyer in Q3 2022 was Artal Group, an estimated $1.48M added.
- The largest Minerva Neurosciences seller in Q3 2022 was Vanguard Group, an estimated $1.95M sold.
Based on aggregated 13F filings for Q3 2022.